Lanadelumab for Treatment of COVID-19 Disease

Radboud University Medical Center43 enrolled

Overview

So far little is very few drugs have demonstrated positive results for treatment of COVID19. Recently the researchers have shown that the use of icatibant in COVID-19 results in a potent decrease in oxygen use. Yet the effect of the three dosages as according to the label dose was insufficient to maintain the clinical improvement in a small group of patients. The researchers argue that with the use of lanadelumab a more lasting effect can be reached due to its longer half life.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

COVID-19

Interventions

lanadelumabBIOLOGICAL

single dose, or two doses administered iv

regular careOTHER

no lanadelumab administration, treated according to regular care

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient is SARS-COV2 positive (PCR) * Without oxygen a saturation below 90% * At least 3L/min oxygen dependent * Patient is 16 years and older Exclusion Criteria: * Has previously participated in this study * Acute myocardial or cerebral ischemic event at time of enrolment * Receiving ACE or ARB inhibitor or comparable drugs that is specified as an intervention in this domain as a usual medication prior to this hospitalization will exclude a patient from receiving that agent * A baseline alanine aminotransferase or an aspartate aminotransferase that is more than five times the upper limit of normal * Patient is known hypersensitive to full human monoclonal antibodies * Patient is pregnant or breast feeding

Locations (4)

Amsterdam UMC

Amsterdam, Netherlands

Rijnstate hospital

Arnhem, Netherlands

Radboudumc

Nijmegen, Netherlands

UMC Utrecht

Utrecht, Netherlands

Outcomes

Primary Outcomes

oxygen

oxygen use in L/min

Time frame: 2 weeks

Secondary Outcomes

adverse events

adverse events after lanadelumab administration

Time frame: 2 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.